Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli DOI Creative Commons
Feiyu Yu, Dejuan Wang,

Haijie Zhang

et al.

mSystems, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

ABSTRACT The global crisis of antimicrobial resistance poses a major threat to human health, underscoring the urgency developing new antibacterial strategies. Antimicrobial peptides (AMPs) are promising alternatives antibiotic therapy, yet potential microbial is great concern. Resistance often accompanied by fitness costs, which may in turn influence spread drug-resistant bacteria and their susceptibility other agents. Herein, we investigate evolutionary trajectory bacterial antibiotics AMPs Escherichia coli , evaluate costs collateral sensitivity strains. We reveal that E. develops antibiotics, particularly ciprofloxacin kanamycin, at notably faster rate than AMPs. Moreover, antibiotic-evolved strains exhibit slightly higher AMP-evolved bacteria, primarily manifested reduced growth swimming motility. Notably, demonstrate trimethoprim-resistant coli, with mutations thyA gene, displays enhanced pexiganan, as evidenced both vitro vivo studies. Overall, our findings shed insights for clinical deployment propose innovative therapeutic strategies combating antibiotic-resistant infections. IMPORTANCE necessitates development anti-infective represent post-antibiotic era. By monitoring eight ten exhibits slower emergence against compared antibiotics. Additionally, these incur significant Most importantly, find some show specific animal infection models, conducive accelerating AMP-based treatment.

Language: Английский

Evolutionary trajectory of bacterial resistance to antibiotics and antimicrobial peptides in Escherichia coli DOI Creative Commons
Feiyu Yu, Dejuan Wang,

Haijie Zhang

et al.

mSystems, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

ABSTRACT The global crisis of antimicrobial resistance poses a major threat to human health, underscoring the urgency developing new antibacterial strategies. Antimicrobial peptides (AMPs) are promising alternatives antibiotic therapy, yet potential microbial is great concern. Resistance often accompanied by fitness costs, which may in turn influence spread drug-resistant bacteria and their susceptibility other agents. Herein, we investigate evolutionary trajectory bacterial antibiotics AMPs Escherichia coli , evaluate costs collateral sensitivity strains. We reveal that E. develops antibiotics, particularly ciprofloxacin kanamycin, at notably faster rate than AMPs. Moreover, antibiotic-evolved strains exhibit slightly higher AMP-evolved bacteria, primarily manifested reduced growth swimming motility. Notably, demonstrate trimethoprim-resistant coli, with mutations thyA gene, displays enhanced pexiganan, as evidenced both vitro vivo studies. Overall, our findings shed insights for clinical deployment propose innovative therapeutic strategies combating antibiotic-resistant infections. IMPORTANCE necessitates development anti-infective represent post-antibiotic era. By monitoring eight ten exhibits slower emergence against compared antibiotics. Additionally, these incur significant Most importantly, find some show specific animal infection models, conducive accelerating AMP-based treatment.

Language: Английский

Citations

0